<DOC>
	<DOCNO>NCT00002700</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy radiation therapy may kill tumor cell . Bone marrow transplantation replace immune cell destroy chemotherapy . PURPOSE : Randomized phase III trial study effectiveness chemotherapy compare without bone marrow transplantation treat patient acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Chemotherapy With Without Bone Marrow Transplantation Treating Patients With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare remission induction , toxicity , duration remission patient newly diagnose acute lymphoblastic leukemia lymphoblastic lymphoma treat prednisone v dexamethasone plus cyclophosphamide , daunorubicin , vincristine induction . - Compare survival disease-free survival patient treat autologous bone marrow transplantation ( BMT ) follow low- high-intensity maintenance chemotherapy cranial irradiation consolidation . - Determine relative disease-free survival patient treat autologous allogeneic BMT identical induction , consolidation , condition regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord center risk group ( high vs standard ) . Induction - Patients randomize 1 2 treatment arm . - Arm I : Patients receive daunorubicin IV day 1-3 15 16 ; cyclophosphamide ( CTX ) IV day 1 8 ; vincristine ( VCR ) IV day 1 , 8 , 15 , 22 ; prednisone IV orally every 8 hour day 1-7 15-21 . - Arm II : Patients receive daunorubicin , CTX , VCR arm I dexamethasone IV orally day 1-8 15-22 . - Patients arm without CNS disease presentation receive CNS prophylaxis comprise methotrexate ( MTX ) intrathecally ( IT ) day 1 , 8 , 15 , 22 . Patients arm CNS disease presentation receive CNS therapy comprise hydrocortisone ( HC ) IT MTX IT alternate cytarabine ( ARA-C ) IT twice week CSF clear . After induction , patient arm proceed consolidation , regardless response . Consolidation - Patients receive ARA-C IV 2 hour every 12 hour day 29-34 mitoxantrone IV day 33-35 . Patients without CNS disease presentation receive CNS prophylaxis comprise MTX IT day 29 . Patients CNS disease presentation receive CNS therapy comprise HC IT MTX IT alternate ARA-C weekly 6 week . Patients achieve complete response ( CR ) day 55-60 receive MTX IV day 64 79 , leucovorin calcium IV orally every 6 hour day 65-67 80-82 , asparaginase IV 1 hour intramuscularly day 65 80 . - Standard-risk patient age 20 achieve CR day 80 assign arm IV group A . Patients achieve CR day 80 genotypically phenotypically HLA-matched family donor , family donor mismatch 1 locus ( A , B , DR ) , HLA-matched unrelated donor proceed group B . Patients achieve CR day 80 eligible autologous bone marrow transplantation ( BMT ) proceed group A . Patients find extremely high risk take study . Group A - Patients randomize 1 2 treatment arm . - Arm III : Autologous bone marrow harvest . Patients receive bone marrow ablation comprise CTX IV 1 hour day -4 -3 total body irradiation day -1 . Autologous bone marrow reinfused day 0 . Beginning month 8 ( 4 month BMT ) , patient receive first maintenance comprise VCR IV , doxorubicin IV , dexamethasone IV ( VAD ) VCR IV , doxorubicin IV , prednisolone IV ( VAP ) day 1-4 29-32 . Patients receive second maintenance comprise oral mercaptopurine daily oral MTX daily begin month 10 continue year 3 . Patients without CNS disease presentation receive CNS prophylaxis comprise MTX IT day 1 29 . Patients CNS disease presentation receive CNS therapy comprise ARA-C IT , MTX IT , HC IT begin 1 month BMT continue monthly 1 year every 3 month year 3 . - Arm IV : Patients receive CTX IV ARA-C IV continuously day 1 , oral mercaptopurine day 8-28 , oral MTX day 8 , 15 , 22 month 4 , 7 , 11 , 13 , 17 , 21 , 25 , 29 . Patients receive MTX IV 30 minute day 1 , leucovorin calcium IV orally every 6 hour day 2-4 , asparaginase IV 1 hour intramuscularly day 2 , oral mercaptopurine day 8-28 , oral MTX day 8 , 15 , 22 month 6 , 10 , 12 , 15 , 19 , 23 , 27 . Patients receive VAD VAP arm III begin month 8 . Patients without CNS disease presentation receive CNS prophylaxis comprise whole brain radiotherapy MTX IT day 1 radiotherapy month 5 . Patients CNS disease presentation receive CNS therapy arm III . Group B - Allogeneic bone marrow harvest . Patients receive bone marrow ablation arm III begin day 100 . Allogeneic bone marrow infuse 15-30 minute day 0 . - Patients group A B CNS disease presentation undergo radiotherapy focal infiltration entry concurrently total body irradiation , whole brain radiotherapy maintenance ( prior CNS irradiation ) . At time study , patient develop marrow relapse ( 5 % leukemic blast bone marrow 2 occasion ) , CNS relapse ( blast CSF , cranial nerve palsy , CNS mass ) , testis extramedullary relapse take study . PROJECTED ACCRUAL : A total 392 patient accrue study within approximately 6 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute lymphoblastic leukemia lymphoblastic lymphoma 30 % blast bone marrow PATIENT CHARACTERISTICS : Age : 15 60 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 2 mg/dL ( unless elevation due leukemic involvement liver ) Renal : Creatinine le 2 mg/dL ( unless elevation due leukemic involvement kidney ) Cardiovascular : No severe cardiac disease Pulmonary : No severe pulmonary disease Other : No severe neurologic metabolic disease HIV negative ( test ) No prior malignancy except nonmelanomatous skin cancer , stage I cervical carcinoma , curatively treated malignancy PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy Endocrine therapy : No prior endocrine therapy Radiotherapy : No prior radiotherapy Surgery : No prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
</DOC>